Novo Nordisk, the giant, has announced a full expansion of its production, reigniting market enthusiasm. Novo Nordisk stated that it plans to invest over 42 billion Danish kroner (approximately over 6 billion US dollars) in the next few years to expand its existing production facilities in Karenburg, Denmark, to meet the production capacity needs of existing and future chronic disease series products, including GLP-1 products.